SCHEMBL17048835

SCHEMBL17048835

CCOC(=O)[C@]1(C)CC[C@@H](n2ncc(C(=O)O)c2Cl)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 1/20 0.36
POLB P06746 3/20 0.35
NR3C1 P04150 2/20 0.34
LMNA P02545 2/20 0.33
AXL P30530 1/20 0.33
TYRO3 Q06418 1/20 0.33
MERTK Q12866 1/20 0.33
HSD11B1 P28845 1/20 0.33
OPRM1 P35372 3/20 0.33
KDM4E B2RXH2 2/20 0.33
PKM P14618 1/20 0.32
MAPT P10636 1/20 0.32
HSD17B10 Q99714 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
OPRD1 P41143 2/20 0.32
OPRK1 P41145 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17048838 1.00 PRMT1 (0.36) PRMT1POLBNR3C1LMNAAXL
SCHEMBL17099119 0.91 LMNA (0.40) PRMT1LMNAKDM4EMAPTHSD17B10
SCHEMBL17099121 0.91 LMNA (0.40) PRMT1LMNAKDM4EMAPTHSD17B10
SCHEMBL17110393 0.88 PRMT1 (0.38) PRMT1POLBLMNAAXLTYRO3
SCHEMBL17048921 0.84 MAPT (0.37) PRMT1POLBOPRM1KDM4EMAPT
SCHEMBL17117869 0.84 HSD17B10 (0.39) PRMT1POLBLMNAAXLTYRO3
SCHEMBL17098721 0.84 MAPT (0.37) PRMT1POLBOPRM1KDM4EMAPT
SCHEMBL17048919 0.84 MAPT (0.37) PRMT1POLBOPRM1KDM4EMAPT
SCHEMBL17110205 0.83 LRRK2 (0.34) POLBNR3C1HSD11B1KDM4ETDP1
SCHEMBL17110424 0.83 PRMT1 (0.37) PRMT1POLBLMNAOPRM1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3110810-B1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LTD (JP) 2018-05-02 EP disclosed
EP-3110810-A1 PYRAZOLE AMIDE DERIVATIVE Teijin Pharma Limited (JP) 2017-01-04 EP disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-9365522-B2 Pyrazole amide derivative AMGEN INC. (US) 2016-06-14 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
US-20150266824-A1 Pyrazole Amide Derivative TEIJIN LIMITED (JP) 2015-09-24 US disclosed
WO-2015129926-A1 PYRAZOLE AMIDE DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2015-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266824-A1 Pyrazole Amide Derivative RORC, RORB, RORA PRMT1 348/4885POLB 4102/4885NR3C1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.